Altimmune, Inc. (Nasdaq: ALT) announced it has begun enrolling patients in the PERFORMA Phase 3 trial, a global, randomized, double-blind ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE